Stock comparison
Eli Lilly
Viking Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$974.4B
Sector
Healthcare
VKTX
Viking Therapeutics
Market cap
$3.49B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | VKTX | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 18F | LLY |
| Benjamin Graham | 86A | 53D | LLY |
| Philip Fisher | 86A | 36D | LLY |
| Peter Lynch | 74B | 10F | LLY |
| Joel Greenblatt | 78C | 0F | LLY |
| Charlie Munger | 85A | 24F | LLY |
| Terry Smith | 77C | 28F | LLY |
Side-by-side metrics
| Metric | LLY | VKTX |
|---|---|---|
| Market cap | $974.4B | $3.49B |
| P/E (TTM) | 36.6x | - |
| EV/EBIT | 34.1x | - |
| ROIC (TTM) | 32.06% | -100.02% |
| Gross margin | 83.51% | 0.0% |
| Net margin | 34.98% | 0.0% |
| Revenue CAGR 5y | 23.17% | - |
| EPS CAGR 5y | 40.81% | - |
| Debt / Equity | 1.4x | - |
| Dividend yield | 0.62% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- ROIC (TTM)32.06%vs -100.02%+132%
- Gross margin83.51%vs 0.0%+100%
- Net margin34.98%vs 0.0%+100%
- Dividend yield0.62%vs 0.0%+100%
VKTX leads on
- EV/EBIT-vs 34.1x+124%
- P/E (TTM)-vs 36.6x+119%
- Debt / Equity-vs 1.4x+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.